RHA (Resilient Hyaluronic Acid) and Juvéderm represent fundamentally different approaches to hyaluronic acid filler engineering, and the distinction matters clinically and economically for practice owners.
RHA, manufactured by Revance, uses a proprietary resilient polymer technology that preserves HA's natural flexibility. The molecule is crosslinked at lower density than traditional fillers, allowing it to compress and move with facial expression rather than resist it. This architecture makes RHA particularly suited to dynamic zones—the perioral area, nasolabial folds, and marionette lines—where rigid filler can appear unnatural or cause palpability complaints. RHA received FDA clearance in December 2021 and comes in three viscosities: RHA 2 (lighter, for fine lines), RHA 3 (medium, for moderate folds), and RHA 4 (robust, for deeper volume). The clinical longevity is typically 12 months, though some practices report 14–15 months in less mobile areas.